×
Home
Archive Submission Guidelines
News Contact
Original article
Crossmark

Investigation of possible effects of Exendin-4 during exposure to mild chronic stress on dehydroepiandrosterone-induced polycystic ovary syndrome in rats

By
Burcu Köksal ,
Burcu Köksal
Sedat Yildiz ,
Sedat Yildiz
Tugba Ozgöcer ,
Tugba Ozgöcer
Azibe Yildiz ,
Azibe Yildiz
Nigar Vardi ,
Nigar Vardi
Özlem Barutcu
Özlem Barutcu

Abstract

The purpose of the study was to investigate the effects of Exendin-4 on polycystic ovary syndrome (PCOS) in rats in chronic mild stress medium. For establishing the PCOS model, dehydroepiandrosterone (DHEA) (6mg/100g) in 0.2ml sesame oil was injected subcutaneously to 21-day old rats (n = 67). In addition, 0.2ml sesame oil was injected subcutaneously to the rats in groups involving solution injection only. At the initial stage of the study, the rats were grouped as control, solution and PCOS, whereas stress and Exendin-4 groups were also added in the second stage of the study. In PCOS groups, Exendin-4 was applied intraperitoneally (10μg/kg/day) in mild chronic stress medium for four weeks. The results revealed that weight, fasting blood glucose, fasting blood insulin and HOMA-IR levels in the rats with PCOS were significantly higher than in the other groups; also, corticosterone levels of stress groups were significantly higher than in the other groups. In addition, harmful effects of PCOS on ovarian tissues were observed in histological examinations. However, after Exendin-4 application in PCOS groups, weight, fasting blood glucose, fasting blood insulin, HOMA-IR and LH/FSH levels were decreased, whereas Exendin-4 application in PCOS group treated with stress was not as effective as the application of Exendin-4 on rats with PCOS. Exendin-4 application also increased the number of healthy follicles in PCOS group, whereas there was no change in the number of healthy follicles in PCOS+Stress group.

 

References

1.
Lecke SB, Morsch DM, Spritzer PM. Association between adipose tissue expression and serum levels of leptin and adiponectin in women with polycystic ovary syndrome. Genetics and Molecular Research. 12(4):4292–6.
2.
Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). Human Reproduction. 2012;27(1):14–24.
3.
Talbott EO, Zborowski JV, Rager JR, Kip KE, Xu X, Orchard TJ. Polycystic Ovarian Syndrome (PCOS): A Significant Contributor to The Overall Burden of Type 2 Diabetes in Women. Journal of Women’s Health. 2007;16(2):191–7.
4.
Homburg R. Pregnancy complications in PCOS. Best Practice & Research Clinical Endocrinology & Metabolism. 2006;20(2):281–92.
5.
Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, et al. Determinants of Abnormal Gonadotropin Secretion in Clinically Defined Women with Polycystic Ovary Syndrome1. The Journal of Clinical Endocrinology & Metabolism. 1997;82(7):2248–56.

Citation

Article metrics

Google scholar: See link

Citations

Crossref Logo

1

Crossref Logo

Kannan Sridharan, Gowri Sivaramakrishnan

(2025)

Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in poly cystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials

Diabetology & Metabolic Syndrome, 17(1)

10.1186/s13098-025-01730-8

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.